According to Nxera Pharma's latest financial reports the company's current EPS (TTM) is -โน68.64. In 2023 the company made an earnings per share (EPS) of -โน53.32 a decrease over its 2022 EPS that were of โน3.08.
Year | EPS | Change |
---|---|---|
2024 (TTM) | -โน66.24 | 24.23% |
2023 | -โน53.32 | -1829.25% |
2022 | โน3.08 | -67.15% |
2021 | โน9.39 | -40.17% |
2020 | โน15.69 | 5.97% |
2019 | โน14.81 | -124.17% |
2018 | -โน61.26 | -157.64% |
2017 | โน106.28 | -691.98% |
2016 | -โน17.95 | -366.52% |
2015 | โน6.74 | -74.61% |
2014 | โน26.53 | 45.12% |
2013 | โน18.28 | -142.56% |
2012 | -โน42.95 | 4.42% |
2011 | -โน41.13 | 18.94% |
2010 | -โน34.58 | -52.47% |
2009 | -โน72.75 | -161% |
2008 | โน119.27 | -205.26% |
2007 | -โน113.31 | 23.33% |
2006 | -โน91.88 | 42.13% |
2005 | -โน64.64 |